Delisting risk
VistaGen Therapeutics (VTGN)
Develops intranasal pherine candidates for psychiatric, women's-health, and cancer-supportive-care conditions.
$0.2500
Pre-market+0.00 (+0.64%)
At close$0.2484(+2.10%)
Something off on this page? Send us feedback.
Next report
Nov 12, 2026
in 70 days
EPS estimate
−$0.37
Revenue estimate
$500.0K
Fiscal quarter
Q2 FY27
EPSReportedEstimate
Jun '25Aug '25Nov '25Feb '26Jun '26Aug '26Aug '26Nov '26
Reported−$0.43−$0.47−$0.54−$0.45−$0.37−$0.30−$0.30Pending
Estimate−$0.52−$0.47−$0.51−$0.51−$0.42−$0.37−$0.37−$0.37
Surprise+17.3%0.0%−5.9%+11.8%+11.9%+17.8%+17.8%—
RevenueReportedEstimate
Jun '25Aug '25Nov '25Feb '26Jun '26Aug '26Aug '26Nov '26
Reported−$15.0K$244.0K$258.0K$303.0K$464.0K$1.5M$1.5MPending
Estimate$209.3K$215.7K$145.8K$364.4K$399.9K$500.0K$500.0K$500.0K
Surprise−107.2%+13.1%+77.0%−16.9%+16.0%+195.2%+195.2%—
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.37 | — | — |
| Aug 2026 | −$0.37 | −$0.30 | +17.8% |
| Aug 2026 | −$0.37 | −$0.30 | +17.8% |
| Jul 2026 | −$0.34 | — | — |
| Jun 2026 | −$0.34 | — | — |
| Jun 2026 | −$0.42 | −$0.37 | +11.9% |
| Feb 2026 | −$0.51 | −$0.45 | +11.8% |
The latest year is open to everyone — the 39 quarters behind it read with an account. Sign in | |||
| Nov 2025 | |||
| Aug 2025 | |||
| Jun 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| Jun 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| Jun 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| Jun 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| Jun 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| Jun 2020 | |||
| Feb 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| Jun 2019 | |||
| Feb 2019 | |||
| Oct 2018 | |||
| Aug 2018 | |||
| Jun 2018 | |||
| Feb 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| Jun 2017 | |||
| Feb 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| Jun 2016 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | −$0.37 | — | — | $500.0K | — | — | — |
| Aug 14, 2026 | −$0.37 | −$0.30 | +17.8% | $500.0K | $1.5M | +195.2% | +0.5% |
| Aug 13, 2026 | −$0.37 | −$0.30 | +17.8% | $500.0K | $1.5M | +195.2% | +2.0% |
| Jul 1, 2026 | −$0.34 | — | — | $401.4K | — | — | — |
| Jun 16, 2026 | −$0.34 | — | — | $399.9K | — | — | — |
| Jun 15, 2026 | −$0.42 | −$0.37 | +11.9% | $399.9K | $464.0K | +16.0% | +20.4% |
| Feb 12, 2026 | −$0.51 | −$0.45 | +11.8% | $364.4K | $303.0K | −16.9% | −7.2% |
The latest year is open to everyone — the 39 quarters behind it read with an account. Sign in | |||||||
| Nov 13, 2025 | |||||||
| Aug 7, 2025 | |||||||
| Jun 17, 2025 | |||||||
| Feb 13, 2025 | |||||||
| Nov 7, 2024 | |||||||
| Aug 13, 2024 | |||||||
| Jun 11, 2024 | |||||||
| Feb 13, 2024 | |||||||
| Nov 9, 2023 | |||||||
| Aug 10, 2023 | |||||||
| Jun 22, 2023 | |||||||
| Feb 7, 2023 | |||||||
| Nov 10, 2022 | |||||||
| Aug 11, 2022 | |||||||
| Jun 23, 2022 | |||||||
| Feb 10, 2022 | |||||||
| Nov 10, 2021 | |||||||
| Aug 12, 2021 | |||||||
| Jun 29, 2021 | |||||||
| Feb 11, 2021 | |||||||
| Nov 12, 2020 | |||||||
| Aug 13, 2020 | |||||||
| Jun 29, 2020 | |||||||
| Feb 13, 2020 | |||||||
| Nov 7, 2019 | |||||||
| Aug 16, 2019 | |||||||
| Jun 25, 2019 | |||||||
| Feb 12, 2019 | |||||||
| Oct 29, 2018 | |||||||
| Aug 14, 2018 | |||||||
| Jun 26, 2018 | |||||||
| Feb 12, 2018 | |||||||
| Nov 9, 2017 | |||||||
| Aug 14, 2017 | |||||||
| Jun 29, 2017 | |||||||
| Feb 13, 2017 | |||||||
| Nov 14, 2016 | |||||||
| Aug 12, 2016 | |||||||
| Jun 24, 2016 | |||||||